Loading...
Beta-blockers, a long-established cornerstone of medical therapy after acute myocardial infarction (AMI), have strong recommendations in AMI treatment guidelines. The supporting evidence, however, predates advances in AMI care such as primary percutaneous coronary intervention and intensive antiplatelet regimens. To update the evidence base, researchers conducted a registry-embedded, randomized trial comparing long-term beta-blocker therapy (metoprolol or bisoprolol) with no beta-blocker in 5020 patients (median age, 65 years; 23% women; 95% from a Swedish national registry) who had a normal left-ventricular ejection fraction (LVEF) after an AMI (35% with ST-segment elevation) for which they had undergone angiography and coronary revascular…